Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study of Intravenous AAVrh10 Vector Expressing GALC in Krabbe Subjects Who Previously Received Hematopoietic Stem Cell Transplantation (REKLAIM)

NCT05739643 is registered in ClinicalTrials.gov with Forge Biologics, Inc as lead sponsor.

NCT NCT05739643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05739643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study of Intravenous AAVrh10 Vector Expressing GALC in Krabbe Subjects Who Previously Received Hematopoietic Stem Cell Transplantation (REKLAIM)
Lead sponsor
Forge Biologics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 3, 2023
Completion date
November 30, 2026
Enrollment
9 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

krabbe disease